The development of renin inhibitors with favorable oral pharmacokinetic profiles has been a longstanding challenge for the pharmaceutical industry. As part of our work to identify inhibitors of BACE1, we have previously developed iminopyrimidinones as a novel pharmacophore for aspartyl protease inhibition. In this letter we describe how we modified substitution around this pharmacophore to develop a potent, selective and orally active renin inhibitor.
Keywords: BACE1; Enzyme inhibitors; Hypertension; Renin inhibitors; Structure-based drug design.
Copyright © 2015 Elsevier Ltd. All rights reserved.